Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Angiotensin Converting Enzyme (ACE) Inhibitors Market Research Report 2019-2025

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Angiotensin Converting Enzyme (ACE) Inhibitors Industry
  • 1.7 COVID-19 Impact: Angiotensin Converting Enzyme (ACE) Inhibitors Market Trends

    • 2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Quarterly Market Size Analysis

    • 2.1 Angiotensin Converting Enzyme (ACE) Inhibitors Business Impact Assessment - COVID-19
      • 2.1.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
      • 2.1.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Quarterly Market Size by Manufacturers, 2019 VS 2020
    • 3.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Factory Price by Manufacturers
    • 3.3 Location of Key Manufacturers Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Factories and Area Served
    • 3.4 Date of Key Manufacturers Enter into Angiotensin Converting Enzyme (ACE) Inhibitors Market
    • 3.5 Key Manufacturers Angiotensin Converting Enzyme (ACE) Inhibitors Product Offered
    • 3.6 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Angiotensin Converting Enzyme (ACE) Inhibitors Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Sulfhydryl-containing Agents
      • 1.4.2 Dicarboxylate-containing Agents
      • 1.4.3 Phosphonate-containing Agents
    • 4.2 By Type, Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size, 2019-2021
      • 4.2.1 By Type, Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Type, 2020-2021
      • 4.2.2 By Type, Global Angiotensin Converting Enzyme (ACE) Inhibitors Price, 2020-2021

    5 Impact of Covid-19 on Angiotensin Converting Enzyme (ACE) Inhibitors Segments, By Application

    • 5.1 Overview
      • 5.5.1 Hypertension
      • 5.5.2 Cardiovascular Diseases
      • 5.5.3 Kidney Diseases
      • 5.5.4 Other
    • 5.2 By Application, Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size, 2019-2021
      • 5.2.1 By Application, Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Application, 2019-2021
      • 5.2.2 By Application, Global Angiotensin Converting Enzyme (ACE) Inhibitors Price, 2020-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Abbott Laboratories
      • 7.1.1 Abbott Laboratories Business Overview
      • 7.1.2 Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Quarterly Production and Revenue, 2020
      • 7.1.3 Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Product Introduction
      • 7.1.4 Abbott Laboratories Response to COVID-19 and Related Developments
    • 7.2 Pfizer
      • 7.2.1 Pfizer Business Overview
      • 7.2.2 Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Quarterly Production and Revenue, 2020
      • 7.2.3 Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Product Introduction
      • 7.2.4 Pfizer Response to COVID-19 and Related Developments
    • 7.3 Novartis
      • 7.3.1 Novartis Business Overview
      • 7.3.2 Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Quarterly Production and Revenue, 2020
      • 7.3.3 Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Product Introduction
      • 7.3.4 Novartis Response to COVID-19 and Related Developments
    • 7.4 Merck
      • 7.4.1 Merck Business Overview
      • 7.4.2 Merck Angiotensin Converting Enzyme (ACE) Inhibitors Quarterly Production and Revenue, 2020
      • 7.4.3 Merck Angiotensin Converting Enzyme (ACE) Inhibitors Product Introduction
      • 7.4.4 Merck Response to COVID-19 and Related Developments
    • 7.5 Astra Zeneca
      • 7.5.1 Astra Zeneca Business Overview
      • 7.5.2 Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Quarterly Production and Revenue, 2020
      • 7.5.3 Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Product Introduction
      • 7.5.4 Astra Zeneca Response to COVID-19 and Related Developments
    • 7.6 Jhonson and Johnson
      • 7.6.1 Jhonson and Johnson Business Overview
      • 7.6.2 Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Quarterly Production and Revenue, 2020
      • 7.6.3 Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Product Introduction
      • 7.6.4 Jhonson and Johnson Response to COVID-19 and Related Developments
    • 7.7 Eli Lilly
      • 7.7.1 Eli Lilly Business Overview
      • 7.7.2 Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Quarterly Production and Revenue, 2020
      • 7.7.3 Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Product Introduction
      • 7.7.4 Eli Lilly Response to COVID-19 and Related Developments
    • 7.8 Sanofi
      • 7.8.1 Sanofi Business Overview
      • 7.8.2 Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Quarterly Production and Revenue, 2020
      • 7.8.3 Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Product Introduction
      • 7.8.4 Sanofi Response to COVID-19 and Related Developments
    • 7.9 Bristol-Myers Squibb
      • 7.9.1 Bristol-Myers Squibb Business Overview
      • 7.9.2 Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Quarterly Production and Revenue, 2020
      • 7.9.3 Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Product Introduction
      • 7.9.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments
    • 7.10 Bayer
      • 7.10.1 Bayer Business Overview
      • 7.10.2 Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Quarterly Production and Revenue, 2020
      • 7.10.3 Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Product Introduction
      • 7.10.4 Bayer Response to COVID-19 and Related Developments
    • 7.11 GSK
      • 7.11.1 GSK Business Overview
      • 7.11.2 GSK Angiotensin Converting Enzyme (ACE) Inhibitors Quarterly Production and Revenue, 2020
      • 7.11.3 GSK Angiotensin Converting Enzyme (ACE) Inhibitors Product Introduction
      • 7.11.4 GSK Response to COVID-19 and Related Developments
    • 7.12 Teva Pharmaceutical
      • 7.12.1 Teva Pharmaceutical Business Overview
      • 7.12.2 Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Quarterly Production and Revenue, 2020
      • 7.12.3 Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Product Introduction
      • 7.12.4 Teva Pharmaceutical Response to COVID-19 and Related Developments

    8 Supply Chain and Sales Channels Analysis

    • 8.1 Angiotensin Converting Enzyme (ACE) Inhibitors Supply Chain Analysis
      • 8.1.1 Angiotensin Converting Enzyme (ACE) Inhibitors Supply Chain Analysis
      • 8.1.2 Covid-19 Impact on Angiotensin Converting Enzyme (ACE) Inhibitors Supply Chain
    • 8.2 Distribution Channels Analysis
      • 8.2.1 Angiotensin Converting Enzyme (ACE) Inhibitors Distribution Channels
      • 8.2.2 Covid-19 Impact on Angiotensin Converting Enzyme (ACE) Inhibitors Distribution Channels
      • 8.2.3 Angiotensin Converting Enzyme (ACE) Inhibitors Distributors
    • 8.3 Angiotensin Converting Enzyme (ACE) Inhibitors Customers

    9 Key Findings

      10 Appendix

      • 10.1 About Us

      This report covers market size and forecasts of Angiotensin Converting Enzyme (ACE) Inhibitors, including the following market information:
      Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
      Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
      Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
      Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K MT)

      Key market players
      Major competitors identified in this market include Abbott Laboratories, Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb, Bayer, GSK, Teva Pharmaceutical, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Sulfhydryl-containing Agents
      Dicarboxylate-containing Agents
      Phosphonate-containing Agents

      Based on the Application:
      Hypertension
      Cardiovascular Diseases
      Kidney Diseases
      Other

      Buy now